1. 143TiPSPECTALUNG: SCREENING PATIENTS WITH THORACIC TUMORS FOR EFFICIENT CLINICAL TRIAL ACCESS. (16th March 2015) Authors: Besse, B.; Menis, J.; Adam, J.; Dziadziuszko, R.; Hasan, B.; Lacroix, L.; Peters, S.; Lacombe, D.A.; O'Brien, M.; Stahel, R.A. Journal: Annals of oncology Issue: Volume 26(2015)Supplement 1 Page Start: i44 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC). (September 2015) Authors: Besse, B.; Johnson, M.; Janne, P.A.; Garassino, M.; Eberhardt, W.E.E.; Besse, B.; Johnson, M.; Janne, P.A.; Garassino, M.; Eberhardt, W.E.E.; Peters, S.; Toh, C.K.; Kurata, T.; Li, Z.; Kowanetz, M.; Mocci, S.; Sandler, A.; Rizvi, N.A. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S717 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 20P Human virome epitope-level antiviral antibody profiling identified the cytomegalovirus (CMV) as the main driver of senescent immune phenotype (SIP) in patients with advanced non-small cell lung cancer (aNSCLC). (December 2022) Authors: Naigeon, M.; Roulleaux Dugage, M.; Danlos, F-X.; De Oliveira, C.; Boselli, L.; Jouniaux, J-M.; Griscelli, F.; Marabelle, A.; Cassard, L.; Roman, G.; Hulett, T.; Besse, B.; Chaput-Gras, N. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 3000 Chemo-radiation (CRT) and mutation profile in stage III Non Small Cell Lung Cancer (NSCLC): An analysis of the prognostic value. Issue 3 (September 2015) Authors: Boros, A.; Lacroix, L.; Lacas, B.; Adam, J.; Pignon, J.P.; Caramella, C.; Planchard, D.; Levy, A.; Montpreville, V.; Deutsch, E.; Besse, B.; Pechoux, C. Le Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 3023 Pan-European survey on thymic malignancies: A collaboration of the EORTC Lung Cancer Group (LCG) with the RYTHMIC network. (September 2015) Authors: Menis, J.; Girard, N.; Hasan, B.; Besse, B. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S604 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 3025 Prognostic value of PDL1 expression in stage III Non-Small Cell Lung Cancer (NSCLC) treated by chemo-radiotherapy (CRT). (September 2015) Authors: Adam, J.; Boros, A.; Lacas, B.; Lacroix, L.; Pignon, J.P.; Caramella, C.; Planchard, D.; Levy, A.; Besse, B.; Pechoux, C. Le Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S604 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 3032A Activity and safety profile of lucitanib in patients with advanced thymic epithelial tumours. (September 2015) Authors: Besse, B.; Girard, N.; Gazzah, A.; Hierro, C.; Felip, E.; De Braud, F.; Camboni, G.; Dubois, F.; Leger, C.; Legrand, F.; Robert, R.; Therasse, P.; Soria, J.C. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S607 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 3076 Tumor control of advanced pulmonary carcinoid tumors with somatostatin analogs: Experience at Gustave Roussy. (September 2015) Authors: Sullivan, I.; Baudin, E.; Guigay, J.; Scoazec, J.Y.; Leboulleux, S.; Berdelou, A.; Ducreux, M.; Malka, D.; Caramella, C.; Besse, B.; Planchard, D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S622 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 3081 Molecular Tumor Board (MTB) in non-small cell lung cancers (NSCLC) to optimize targeted therapies: 4 years' experience at Gustave Roussy. (September 2015) Authors: Planchard, D.; Faivre, L.; Sullivan, I.; Kahn-charpy, V.; Lacroix, L.; Auger, N.; Adam, J.; De Montpreville, V. Thomas; Dorfmuller, P.; Pechoux, C. Le; Chevalier, T. Le; Gazzah, A.; Remon, J.; Bescher, G.; Soria, J.C.; Pignon, J.P.; Besse, B. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S624 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. 3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC). (September 2015) Authors: Cho, B.C.; Dy, G.K.; Govindan, R.; Kim, D.W.; Pennell, N.A.; Zalcman, G.; Besse, B.; Nogai, H.; Rajagopalan, P.; Ocker, M.; Barlesi, F. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S634 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗